查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584095

糖肽抗生素市场，按给药途径、按药物类型、按适应症、按最终用户、按配销通路、按国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Glycopeptide Antibiotics Market, By Route of Administration, By Drug Type, By Indication, By End User, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年糖肽抗生素市场规模为32.4073亿美元，2024年至2032年复合年增长率为7.20%。

糖肽抗生素市场-市场动态

癌症和传染病发生率上升推动市场需求

糖肽抗生素透过阻断肽聚醣的产生来抑制细菌细胞壁的合成，这使得它们对于治疗对β-内酰胺和其他抗生素具有抗药性的多重抗药性金黄色葡萄球菌(MRSA) 和肠球菌感染至关重要。它们也是对 β-内酰胺过敏的患者的替代品。在癌症和传染病发病率上升的推动下，糖肽抗生素市场预计在未来几年将显着增长。例如，美国疾病管制与预防中心 (CDC) 报告 2019 年新增资料病例 1,752,735 例，癌症相关死亡 599,589 例。前列腺癌、非何杰金氏淋巴瘤是最常见的恶性肿瘤。不断增加的癌症负担增加了对抗生素控制感染的需求，从而促进了市场成长。此外，肠球菌感染和结核病等传染病的流行预计将进一步推动对糖肽抗生素的需求。根据 CDC 2022 年 9 月的资料，美国 2019 年记录了 8,916 例结核病病例。例如，2021年7月，艾伯维公司的DALVANCE获得美国FDA批准，用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI），为糖肽抗生素市场的预期成长做出了贡献。

糖肽抗生素市场-关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 7.20% 左右的复合年增长率成长

根据药物类型细分，万古霉素预计将在 2023 年显示最大市场份额

根据适应症细分，皮肤和结构感染是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

糖肽抗生素市场-細項分析：

全球糖肽抗生素市场根据给药途径、药物类型、适应症、最终用户、配销通路和地区进行细分。

市场依药物类型分为四类：万古霉素、达巴万星、奥利万星、其他。在糖肽类抗生素市场，万古霉素因其长期的临床使用和对严重革兰氏阳性菌感染，特别是耐甲氧西林金黄色葡萄球菌（MRSA）的疗效而被证明有效，仍然是主导药物。它在医院的广泛使用，加上强大的安全性和广泛的临床证据，巩固了其领导地位。儘管达巴万星和奥利万星等较新的替代品具有延长给药间隔等优点，但它们尚未达到万古霉素的市场份额。这主要是由于成本较高以及标准治疗方案中对万古霉素的既定偏好。

根据适应症，市场分为两类：皮肤和结构性感染、脑膜炎、艰难梭菌感染、小肠结肠炎等。在适应症领域，皮肤和结构感染占据最大的市场份额，这是由于其在医疗环境中的高发生率和抗生素抗药性细菌发生率的上升所推动的。这些病例需要可靠的治疗，因此糖肽抗生素至关重要。儘管其他病症（例如艰难梭菌感染和脑膜炎）也很重要，但皮肤和结构感染的流行和严重性质确保了它们在糖肽抗生素市场中的主导地位。

糖肽抗生素市场-地理洞察

北美是糖肽抗生素市场的主导地区，这主要是由于其先进的医疗基础设施、抗生素抗药性感染的高盛行率以及在研发方面的大量投资。该地区的医院是这些抗生素（尤其是万古霉素）的主要消费者，用于治疗 MRSA 等严重的革兰氏阳性感染。此外，支持性监管框架和对感染控制的高度重视导致对糖肽抗生素的需求不断增长。该地区主要製药公司的存在和正在进行的临床试验进一步增强了其市场领导地位。

糖肽抗生素市场-竞争格局：

糖肽抗生素市场的公司采取各种策略来增强竞争力并确保产品可用性。这些努力的核心是研究和开发，重点是改进现有药物配方并探索现有抗生素的新治疗适应症。与医疗机构合作进行临床试验很常见，产生关键资料来支持这些治疗的有效性和安全性。监管策略通常包括寻求快速通道指定，以加快新疗法或改良疗法的审批流程。此外，有针对性的行销活动旨在教育医疗保健专业人员了解糖肽在管理抗药性感染中的关键作用。此外，该公司还参与策略定价和报销谈判，以确保更广泛地获得这些基本抗生素，促进其在临床实践中的可持续使用。一些合作伙伴关係和产品发布促进了市场的成长。

最新进展：

2021年7月，艾伯维公司的DALVANCE获得美国FDA批准，这是一种用于治疗儿科患者急性细菌性皮肤和皮肤结构感染的抗生素。同样，2020年7月，山德士国际有限公司在美国市场推出了500毫克达托霉素注射液，用于治疗复杂的皮肤感染和某些血液感染。这些发展正在推动市场的扩张。

目录

第 1 章：糖肽抗生素市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 依给药途径分類的糖肽抗生素市场片段
    • 按药物类型分類的糖肽抗生素市场片段
    • 糖肽抗生素市场片段（按适应症）
    • 最终用户的糖肽抗生素市场片段
    • 按配销通路分類的糖肽抗生素市场片段
    • 按国家/地区分類的糖肽抗生素市场片段
    • 按地区分類的糖肽抗生素市场片段
  • 竞争洞察

第 3 章：糖肽抗生素主要市场趋势

  • 糖肽抗生素市场驱动因素
    • 市场驱动因素的影响分析
  • 糖肽类抗生素市场限制
    • 市场限制影响分析
  • 糖肽抗生素市场机会
  • 糖肽抗生素市场未来趋势

第 4 章：糖肽抗生素产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：糖肽抗生素市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：糖肽抗生素市场格局

  • 2023 年糖肽抗生素市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：糖肽抗生素市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 注射用
    • 其他的

第 8 章：糖肽抗生素市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 万古霉素
    • 达巴万星
    • 奥利万星
    • 其他的

第 9 章：糖肽抗生素市场 - 按适应症

  • 概述
    • 按指标分類的细分市场占有率分析
    • 皮肤和结构感染
    • 脑膜炎
    • 艰难梭菌感染
    • 小肠结肠炎
    • 其他的

第 10 章：糖肽抗生素市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第 11 章：糖肽抗生素市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局
    • 其他的

第 12 章：糖肽抗生素市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美糖肽抗生素主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按最终用户）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲糖肽抗生素主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按最终用户）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区糖肽抗生素主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按最终用户）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲糖肽抗生素主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲糖肽抗生素主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模及预测（按最终用户）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章：主要供应商分析-糖肽抗生素产业

  • 竞争仪表板
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4085

REPORT HIGHLIGHT

Glycopeptide Antibiotics Market size was valued at USD 3,240.73 Million in 2023, expanding at a CAGR of 7.20% from 2024 to 2032.

Glycopeptide antibiotics, such as vancomycin and teicoplanin, are primarily used to treat severe Gram-positive bacterial infections. They function by inhibiting bacterial cell wall synthesis, which is essential for bacterial growth and structural integrity. Vancomycin is often used to manage infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile. These antibiotics are typically administered intravenously for systemic infections, while oral formulations are used to treat gastrointestinal infections. Due to their effectiveness against drug-resistant bacteria, glycopeptide antibiotics are crucial in hospital settings, particularly for managing complex infections and in surgical prophylaxis.

Glycopeptide Antibiotics Market- Market Dynamics

Increasing incidence of cancer and infectious diseases to propel market demand

Glycopeptide antibiotics inhibit bacterial cell wall synthesis by blocking peptidoglycan production, making them essential for treating multi-resistant Staphylococcus aureus (MRSA) and enterococcal infections that are resistant to beta-lactams and other antibiotics. They are also an alternative for patients allergic to beta-lactams. The market for glycopeptide antibiotics is expected to grow significantly in the coming years, driven by the rising incidence of cancer and infectious diseases. For example, the U.S. Centers for Disease Control and Prevention (CDC) reported 1,752,735 new cancer cases and 599,589 cancer-related deaths in 2019. Additionally, Globocan 2020 data showed 457,960 new cancer cases and 179,648 deaths in the U.K., with breast, prostate, and Non-Hodgkin's lymphoma being the most common malignancies. This rising cancer burden is increasing the demand for antibiotics to manage infections, boosting market growth. Moreover, the prevalence of infectious diseases, such as enterococcal infections and tuberculosis, is expected to further drive the demand for glycopeptide antibiotics. According to CDC data from September 2022, the U.S. recorded 8,916 tuberculosis cases in 2019. Additionally, new product approvals for treating infectious diseases are propelling market expansion. For instance, in July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, used in the treatment of acute bacterial skin and skin structure infections (ABSSSI), contributing to the anticipated growth of the glycopeptide antibiotic market.

Glycopeptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2024-2032)

Based on Drug Type segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication segmentation, skin and structure Infection was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Glycopeptide Antibiotics Market- Segmentation Analysis:

The Global Glycopeptide Antibiotics Market is segmented on the basis of Route of Administration, Drug Type, Indication, End User, Distribution Channel, and Region.

The market is divided into four categories based on Drug Type: Vancomycin, Dalbavancin, Oritavancin, Others. In the glycopeptide antibiotics market, Vancomycin remains the dominant drug due to its long-standing clinical use and proven efficacy against serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). Its widespread use in hospitals, combined with a strong safety profile and extensive clinical evidence, reinforces its leadership. Although newer alternatives like Dalbavancin and Oritavancin offer benefits such as extended dosing intervals, they have not yet achieved Vancomycin's market share. This is primarily due to higher costs and the well-established preference for Vancomycin in standard treatment protocols.

The market is divided into two categories based on indication: Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis and Others. In the indication segment, skin and structure infections hold the largest market share, driven by their high occurrence in healthcare environments and the rising incidence of antibiotic-resistant bacteria. The need for reliable treatments in these cases has made glycopeptide antibiotics essential. While other conditions, such as Clostridioides difficile infections and meningitis, are also important, the prevalence and critical nature of skin and structure infections ensure their dominant role in the glycopeptide antibiotics market.

Glycopeptide Antibiotics Market- Geographical Insights

North America is the dominating region in the glycopeptide antibiotics market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for glycopeptide antibiotics. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Glycopeptide Antibiotics Market- Competitive Landscape:

Companies in the glycopeptide antibiotics market adopt various strategies to enhance competitiveness and ensure product availability. Central to these efforts is research and development, with a focus on improving existing drug formulations and exploring new therapeutic indications for current antibiotics. Collaborations with healthcare institutions for clinical trials are common, generating critical data to support the efficacy and safety of these treatments. Regulatory strategies often include pursuing fast-track designations to expedite the approval process for new or modified treatments. Furthermore, targeted marketing campaigns aim to educate healthcare professionals about the critical role of glycopeptides in managing drug-resistant infections. In addition, companies engage in strategic pricing and reimbursement negotiations to ensure broader access to these essential antibiotics, facilitating their sustainable use in clinical practice. Several partnerships and product launches have contributed to the market's growth.

Recent Developments:

In July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, an antibiotic used to treat acute bacterial skin and skin structure infections in pediatric patients. Similarly, in July 2020, Sandoz International GmbH introduced a 500 mg Daptomycin injection in the U.S. market to treat complicated skin infections and certain bloodstream infections. These developments are boosting the market's expansion.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Vancomycin
  • Dalbavancin
  • Oritavancin
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Skin and Structure Infection
  • Meningitis
  • Clostridioides Difficile Infection
  • Enterocolitis
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Glycopeptide Antibiotics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Glycopeptide Antibiotics Market Snippet by Route of Administration
    • 2.1.2. Glycopeptide Antibiotics Market Snippet by Drug Type
    • 2.1.3. Glycopeptide Antibiotics Market Snippet by Indication
    • 2.1.4. Glycopeptide Antibiotics Market Snippet by End User
    • 2.1.5. Glycopeptide Antibiotics Market Snippet by Distribution Channel
    • 2.1.6. Glycopeptide Antibiotics Market Snippet by Country
    • 2.1.7. Glycopeptide Antibiotics Market Snippet by Region
  • 2.2. Competitive Insights

3. Glycopeptide Antibiotics Key Market Trends

  • 3.1. Glycopeptide Antibiotics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Glycopeptide Antibiotics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Glycopeptide Antibiotics Market Opportunities
  • 3.4. Glycopeptide Antibiotics Market Future Trends

4. Glycopeptide Antibiotics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Glycopeptide Antibiotics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Glycopeptide Antibiotics Market Landscape

  • 6.1. Glycopeptide Antibiotics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Glycopeptide Antibiotics Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Parenteral
    • 7.1.4. Others

8. Glycopeptide Antibiotics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Vancomycin
    • 8.1.3. Dalbavancin
    • 8.1.4. Oritavancin
    • 8.1.5. Others

9. Glycopeptide Antibiotics Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Skin and Structure Infection
    • 9.1.3. Meningitis
    • 9.1.4. Clostridioides Difficile Infection
    • 9.1.5. Enterocolitis
    • 9.1.6. Others

10. Glycopeptide Antibiotics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospital
    • 10.1.3. Specialty Clinics
    • 10.1.4. Homecare
    • 10.1.5. Others

11. Glycopeptide Antibiotics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies
    • 11.1.5. Others

12. Glycopeptide Antibiotics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Glycopeptide Antibiotics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Glycopeptide Antibiotics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Glycopeptide Antibiotics Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Glycopeptide Antibiotics Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Glycopeptide Antibiotics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Glycopeptide Antibiotics Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. F. Hoffmann-La Roche Ltd.
    • 13.2.2. NATCO Pharma Limited
    • 13.2.3. Teva Pharmaceutical Industries Ltd
    • 13.2.4. LUPIN Limited
    • 13.2.5. Amneal pharmaceuticals LLC
    • 13.2.6. Zydus Cadila
    • 13.2.7. Sun Pharmaceutical Industries Ltd.
    • 13.2.8. Alembic Pharmaceuticals Limited
    • 13.2.9. Mylan N.V.
    • 13.2.10. Hetero Group
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us